Driven by huge clinical demand and clear clinical value, the...

Moomoo AI Oct 29, 2023 23:19

Driven by huge clinical demand and clear clinical value, the company believes that BA1104 has broad market prospects. The company will also actively explore the combined therapeutic potential of this product with the company's other innovative antibody drugs, which will further promote the development of the company's innovative drugs.

Boan Biotech (06955): China phase III clinical trial of navulliumab injection (BA1104) completed the first patient enrolled

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

1883 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4314Followers

0Following

9471Visitors